Familiar Therapeutics, a Redwood City, California-based biotechnology company developing treatments for companion animals, has launched with $5 million in seed funding to adapt advances in human medicine for dogs and cats. The financing was led by Pioneer Fund, Icehouse Ventures, and BreakTHRU, an investment syndicate comprising animal health industry leaders and veterinarians, with additional participation from angel investors.
Founded in May 2026 by entrepreneurs Elizabeth Iorns and Dan Knox, Familiar is developing a portfolio of veterinary medicines based on drugs that have already undergone substantial research for human diseases.
The company aims to address the gap between advances in human therapeutics and the limited treatment options available for pets suffering from serious illnesses.
Although dogs and cats can develop many of the same diseases as humans, relatively few new medications are approved specifically for companion animals each year. Familiar noted that the U.S. Food and Drug Administration approves fewer than 10 new companion animal drugs annually, compared with more than 50 for human use.
As a result, veterinarians frequently rely on medications developed for humans, sometimes without comprehensive dosing or safety data specific to the animal species being treated.
Familiar intends to address this challenge by licensing veterinary rights to promising treatments from pharmaceutical and biotechnology companies, then conducting the animal-specific research, manufacturing development, and regulatory work required for veterinary approval.
By building on existing human research, the company believes it can accelerate development compared with the seven to ten years typically required to bring a new animal medicine to market.
During its first five months, Familiar established a pipeline of 13 programs, comprising four lead candidates and nine earlier-stage projects. The portfolio spans oncology, neurology, cardiology, respiratory conditions, and immunology.
The company has also established several pharmaceutical partnerships, filed a provisional patent, and opened two investigational new animal drug files with the FDA’s Center for Veterinary Medicine.
Its most advanced program, FAM-010, is being developed to treat hemangiosarcoma, an aggressive cancer affecting dogs for which no FDA-approved treatment currently exists.
Familiar plans to begin a pilot clinical study of FAM-010 at the University of Illinois College of Veterinary Medicine in fall 2026. The study will be led by Timothy M. Fan, DVM, PhD.
Other lead programs address intervertebral disc disease, which can cause pain and paralysis in dogs; respiratory disorders affecting flat-faced breeds such as French Bulldogs and Pugs; and immune-mediated diseases.
The company intends to pursue FDA approval for its programs and may seek conditional approval where permitted for treatments addressing serious unmet veterinary needs.
Iorns and Knox previously co-founded Science Exchange, a Y Combinator-backed research and development outsourcing platform acquired in 2024.
Their interest in veterinary therapeutics was influenced by Iorns’ experience seeking treatment for her French Bulldog, Lily, following a terminal brain tumor diagnosis in 2020.
That work eventually contributed to a collaboration involving a checkpoint inhibitor and a personalized cancer vaccine developed with Ardent Animal Health. A subsequent registrational study involving dogs with osteosarcoma recently met its endpoint.
Familiar has assembled an animal health development team with experience contributing to more than 30 FDA approvals at companies including Zoetis, Elanco, and Bayer Animal Health. It also maintains a 12-member scientific advisory board.
The $5 million seed investment will support clinical development of Familiar’s lead programs and continued advancement of its broader pipeline.
All Familiar drug candidates remain investigational and have not received FDA approval.
KEY QUOTES:
“Our goal is to give vets proven, FDA-approved treatments that change the course of serious diseases in dogs and cats, where today they often have very few options. The science is often already there, and when you begin with a drug that already has years of human research behind it, the veterinary work can move much faster. Familiar is built to do that work all the way through to approval and commercialization, so those medicines can actually reach pets.”
Elizabeth Iorns, Co-Founder And CEO Of Familiar Therapeutics
“The science flows both ways. When we develop a drug for dogs and cats with naturally occurring disease, the evidence we generate can also inform and de-risk our biopharma partners’ human programs. Those partners keep their human rights and share in veterinary sales, so they earn a faster return on research they’ve already paid for. That’s a big part of why we’ve been able to sign partners so quickly.”
Dan Knox, Co-Founder And COO Of Familiar Therapeutics
“Elizabeth and Dan are two of New Zealand’s most accomplished founders. The market for veterinary medicines is growing, and pet owners now expect the same standard of care for their animals that they get themselves. We have high conviction that Elizabeth, Dan and their team are the right people to close the gap between human and veterinary medicine, and we’re proud to have been Familiar’s first institutional investor.”
Robbie Paul, CEO Of Icehouse Ventures
